ArticleRNA (New York, N.Y.)2008
Selection and characterization of anti-NF-kappaB p65 RNA aptamers.
Article in RNA (New York, N.Y.), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 48 citations in OpenAlex.
- RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases.Pharmacological research · 2025Review
- CRISPR-Hybrid: A CRISPR-Mediated Intracellular Directed Evolution Platform for RNA Aptamers.Nature communications · 2025Article
- Noncoding RNAs in skeletal development and disorders.Biological research · 2024Review
- Dynamic Nanostructures for Conditional Activation and Deactivation of Biological Pathways.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Review
- An aptamer interacting with heat shock protein 70 shows therapeutic effects and prognostic ability in serous ovarian cancer.Molecular therapy. Nucleic acids · 2021Article
- Aptamers: A Review of Their Chemical Properties and Modifications for Therapeutic Application.Molecules (Basel, Switzerland) · 2019Review
- Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts.Nature biotechnology · 2019Article
- Aptamers: Uptake mechanisms and intracellular applications.Advanced drug delivery reviews · 2018Review
- Article
- Molecular Elucidation of Disease Biomarkers at the Interface of Chemistry and Biology.Journal of the American Chemical Society · 2017Article
- Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.Nucleic acid therapeutics · 2016Review
- RNA aptamer inhibitors of a restriction endonuclease.Nucleic acids research · 2015Article
- MYB elongation is regulated by the nucleic acid binding of NFκB p50 to the intronic stem-loop region.PloS one · 2015Article
- The structure, function and evolution of proteins that bind DNA and RNA.Nature reviews. Molecular cell biology · 2014Review
- Article
- Pirin is an iron-dependent redox regulator of NF-κB.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Quantification of activated NF-kappaB/RelA complexes using ssDNA aptamer affinity-stable isotope dilution-selected reaction monitoring-mass spectrometry.Molecular & cellular proteomics : MCP · 2011Article
- Reprogramming cellular behavior with RNA controllers responsive to endogenous proteins.Science (New York, N.Y.) · 2010Article
- In vitro and ex vivo selection procedures for identifying potentially therapeutic DNA and RNA molecules.Molecules (Basel, Switzerland) · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
NF-kappaB transcription factors include a group of five mammalian proteins that form hetero- or homodimers and regulate hundreds of target genes involved in acute inflammation, HIV-1 transcription activation, and resistance to cancer therapy. We previously used in vitro selection to develop a small RNA aptamer (anti-p50) that binds the DNA-binding domain of NF-kappaB p50(2) with low nanomolar affinity but does not bind NF-kappaB p65(2). Here, we report the in vitro selection of anti-NF-kappaB p65 RNA aptamers using parallel in vitro selections with either a fully randomized RNA library or a degenerate RNA library based on the primary sequence of the 31-nucleotide anti-p50 RNA aptamer. We report the characterization of these aptamers with respect to NF-kappaB target specificity, affinity, minimal sequence requirements, secondary structure, and competition with DNA kappaB sites. These results expand opportunities for artificial inhibition of NF-kappaB transcription factor dimers containing p65 subunits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.